Raymond Woo Sells 4,887 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.33, for a total value of $118,900.71. Following the transaction, the chief technology officer owned 203,118 shares of the company’s stock, valued at $4,941,860.94. This trade represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Trading Down 4.0%

NASDAQ:CBLL traded down $0.98 on Thursday, reaching $23.43. 220,126 shares of the stock traded hands, compared to its average volume of 327,873. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The company’s 50 day moving average is $21.03 and its 200-day moving average is $19.61. The firm has a market capitalization of $899.24 million, a price-to-earnings ratio of -13.31 and a beta of 0.95.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. Equities research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group boosted their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. BTIG Research raised their price objective on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 28th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $24.40.

Institutional Investors Weigh In On CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of CBLL. BlackRock Inc. purchased a new position in CeriBell during the 2nd quarter worth $37,657,000. Vanguard Group Inc. raised its holdings in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after purchasing an additional 147,013 shares during the last quarter. KCM Capital Inc raised its holdings in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the last quarter. Yu Fan lifted its position in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.